Buchang Pharmaceutical Subsidiary Acquires Angong Niuhuang Wan Production Approval and Technology Ownership for 9.4 Million Yuan

财中社··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Buchang Pharmaceutical announced on September 29 that its wholly owned subsidiary Tonghua Guhong signed a technology transfer contract with Jilin Province Tiantai Pharmaceutical Co., Ltd. to acquire the production approval and technology ownership of Angong Niuhuang Wan for a transfer price of 9.4 million yuan. In the first half of 2026, Buchang Pharmaceutical achieved revenue of 5.003 billion yuan and net profit attributable to the parent of 503 million yuan.

Impact on assets 1

Others▲ · 1 stocks
Shandong Buchang Pharmaceuticals Co Ltd
603858
▲ PositiveCapitalrelevance

Wholly owned subsidiary Tonghua Guhong acquires Angong Niuhuang Wan production approval and technology for 9.4 million yuan, expanding its product portfolio.

Off-coverage companies 2

Jilin Tiantai Pharmaceutical Co., Ltd.Private▼ Negative
Capitalrelevance

Jilin Tiantai Pharmaceutical transfers ownership of its Angong Niuhuang Wan production approval and technology for 9.4 million yuan.

通化谷红制药有限公司Private▲ Positive
Capitalrelevance

Tonghua Guhong, Buchang's wholly owned subsidiary, is the acquirer of the Angong Niuhuang Wan production approval and technology.

© 2026 MarketIVNews